Janone earns us patent for the use of its novel formulation of low-dose naltrexone, jan123, to treat chronic pain

The broad patent coverage is a major milestone for the commercial success of jan123 las vegas , aug. 29, 2023 /prnewswire/ -- janone (nasdaq: jan), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a us patent for its innovative formulation of low-dose naltrexone, jan123, for treating pain. the broad patent coverage is a major milestone for the commercial success of jan123  jan123 is being developed to treat complex regional pain syndrome (crps), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
JAN Ratings Summary
JAN Quant Ranking